Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Atara Biotherapeutics, Inc. (ATRA)

Atara Biotherapeutics adds Brian Cherry to board; stockholders re-elect directors at June 9 meeting

Neutral Impact 2 of 5 leadership Written later

Atara Biotherapeutics appointed Brian Cherry as a Class I director effective June 11, 2026, placing him on the Audit Committee, and granted him 24,000 restricted stock units. At its June 9, 2026 annual meeting, stockholders elected two director nominees, approved an advisory say-on-pay vote, approved a 400,000-share increase to the 2024 Equity Incentive Plan, and ratified Deloitte & Touche LLP as auditor.

Key points

  • Brian Cherry appointed Class I director and Audit Committee member, effective June 11, 2026
  • Initial award of 24,000 restricted stock units vesting annually over three years; annual cash retainer of $55,000
  • Stockholders elected AnhCo Nguyen Ph.D. (3,543,113 for) and Nachi Subramanian (2,581,435 for) to serve until the 2029 annual meeting
  • Stockholders approved the equity plan amendment adding 400,000 shares and ratified Deloitte & Touche LLP for fiscal 2026

The filing

CompanyAtara Biotherapeutics, Inc. (ATRA)
Form8-K, current report
Filed with the SECJun 12, 2026, 4:05 PM ET
Accession number0001213900-26-068264

Items reported: 5.02 Director / Officer Change5.07 Shareholder Vote Results

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:38 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on June 12, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.